Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Shandong Xinhua Pharmaceutical Company Limited Class H ( (HK:0719) ) just unveiled an update.
Shandong Xinhua Pharmaceutical Company Limited has received approval from the National Medical Products Administration for a change in the marketing license holder for its Avatrombopag Maleate Tablets. This approval follows a transfer agreement with Shanghai Desenuo Pharmaceutical Group, which includes the transfer of all related technical ownership rights to Xinhua Pharmaceutical. This strategic move is expected to enhance Xinhua Pharmaceutical’s market position and operational capabilities in the pharmaceutical sector.
More about Shandong Xinhua Pharmaceutical Company Limited Class H
Shandong Xinhua Pharmaceutical Company Limited operates in the pharmaceutical industry, focusing on the production and marketing of prescription drugs. The company is based in the People’s Republic of China and is involved in the development and commercialization of pharmaceutical products, including Avatrombopag Maleate Tablets.
Average Trading Volume: 4,889,496
Technical Sentiment Signal: Buy
Current Market Cap: HK$9.26B
See more data about 0719 stock on TipRanks’ Stock Analysis page.